Patents by Inventor Shuen-lu Hung

Shuen-lu Hung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9562268
    Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: February 7, 2017
    Assignee: Academia Sinica
    Inventors: Yuan-Tsong Chen, Shuen-lu Hung, Wen-hung Chung, Jer-Yuarn Wu
  • Publication number: 20130330724
    Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Academia Sinica
    Inventors: Yuan-Tsong Chen, Shuen-lu Hung, Wen-hung Chung, Jer-Yuarn Wu
  • Publication number: 20110014215
    Abstract: Disclosed are uses of granulysin in methods of diagnosing or treating autoimmune disorders.
    Type: Application
    Filed: April 21, 2010
    Publication date: January 20, 2011
    Applicants: Academia Sinica, Chang Gung Medical Foundation, Linkou Branch
    Inventors: Yuan-Tsong Chen, Wen-Hung Chung, Shuen-lu Hung
  • Publication number: 20080145846
    Abstract: This invention relates to a method of determining the presence of certain HLA alleles, such as HLA-B*1502 or HLA-B*5801, and a kit for carrying out this method. Also disclosed is a method for assessing whether a patient is at risk for developing adverse drug reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or hypersensitivity syndrome) based on the presence or absence of a genetic marker (e.g., HLA-B*1502, HLA-B*5801, or HLA-B*4601).
    Type: Application
    Filed: May 11, 2007
    Publication date: June 19, 2008
    Applicants: Academia Sinica, PharmiGene Inc.
    Inventors: Yuan-Tsong Chen, Shuen-lu Hung, Chih-Lung Shen, Chi-Feng Chang, Hsin-Yu Lin, Wei-Hsuan Chen
  • Publication number: 20080050382
    Abstract: Disclosed are uses of granulysin in methods of diagnosing or treating autoimmune disorders.
    Type: Application
    Filed: June 22, 2007
    Publication date: February 28, 2008
    Applicant: Academia Sinica
    Inventors: Yuan-Tsong Chen, Wen-Hung Chung, Shuen-lu Hung